Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00283049 · ClinicalTrials.gov registry record · Phase 4
Insulin Glargine Injection Treatment in Place of Thiazolidinedione (TZD), Sulfonylurea, or Metformin in Triple Agent Therapy for Type 2 Diabetes Mellitus (T2DM) Adult Subjects With Unsatisfactory Control
A Phase 4 study, sponsored by Sanofi.
- Terminated
- Registry status
- Phase 4
- Development phase
- 390
- Enrollment target
NCT00283049: Clinical Trial Phase 4 study, sponsored by Sanofi.
NCT00283049 is a Phase 4 study that was terminated before completion, run by Sanofi. The registered enrollment target is 390 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (25% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00283049, a Phase 4 study, was terminated before completion, sponsored by Sanofi.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 390 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the change in hemoglobin A1c (HbA1c) from baseline to Week 12 between the 3 treatment arms.
Interventions
- DRUG Insulin Glargine
- DRUG Insulin Glulisine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 390 participants |
| Start Date | 2006-02 |
| Est. Completion | 2008-11 |
| Phase | Phase 4 |
Why NCT00283049 stopped before completion
NCT00283049 is an interventional study that assigns participants to a tested intervention. The registered 390 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (25% lower).
The record links to 0 conditions, and to 2 interventions - of which Insulin Glargine is the first listed.
NCT00283049 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00283049 about?
NCT00283049 is a clinical study titled "Insulin Glargine Injection Treatment in Place of Thiazolidinedione (TZD), Sulfonylurea, or Metformin in Triple Agent Therapy for Type 2 Diabetes Mellitus (T2DM) Adult Subjects With Unsatisfactory Control". The purpose of this study is to compare the change in hemoglobin A1c (HbA1c) from baseline to Week 12 between the 3 treatment arms.
What is the current status of trial NCT00283049?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 390 participants. The study started on 2006-02. Estimated completion is 2008-11.
What interventions are being tested in trial NCT00283049?
The interventions under investigation include: Insulin Glargine (DRUG), Insulin Glulisine (DRUG).
Who is sponsoring clinical trial NCT00283049?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00283049's enrollment target sits among peer trials
390 221st of 2000 higher than 1,779 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00397111 · 390 participants
Development of Magnetic Resonance Imaging Techniques for Studying Mood and Anxiety Disorders
- NCT05335928 · 390 participants · Phase 3
Abatacept in Immune Checkpoint Inhibitor Myocarditis
- NCT05445960 · 390 participants · NA
Correlation Between Intraoperative Tourniquet Use and Limb pH, Functional Measures and Patient-reported Outcomes After Ankle Fracture Surgery
- NCT05997615 · 390 participants · Phase 1
Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5500 (AMX-500) in Prostate Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia